InvestorsHub Logo
Followers 20
Posts 1187
Boards Moderated 0
Alias Born 05/06/2014

Re: numbersarefun post# 17192

Friday, 08/26/2016 5:23:19 PM

Friday, August 26, 2016 5:23:19 PM

Post# of 38634

Maybe Par Pharma would like to also sell a branded oxycodone.

PAR had never crossed my mind... but looking into it... it's not a bad fit.
Went through their entire 37 page catalog of what they sell - very impressive.
http://www.parpharm.com/products/product-catalog.php
They list Focalin 15 and 30 mg which are IPCI's of course... but beside that, only Keppra and Lamictal are duplicated between IPCI and PAR... A complete package deal would be quite nice and fit PAR's requisite.
We are focused on developing products with significant barriers to entry and longer life cycles.
We are interested in modified-released oral solid dosage forms
For specialty generic pharmaceutical product development companies, we use a variety of deal structures, ranging from free-for-service to profit-sharing collaborations. Our portfolio and new-product partnering strategy is focused on first-to-file opportunities as well as challenging products with unusual barriers to entry.

So... anyone think that Dominick Della Penna is talking to Paul Campanelli.

Although a deal would need to go through the parent company ENDO which has Opana and Percocet... but I believe they are not ADF drugs.